Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription

Posted September 10, 2007

Ranbaxy Gains Approval To Manufacture And Market Carvedilol Tablets In The U.S. Market
Analysis of: Ranbaxy Gains Approval To Manufacture And Market Carvedilol Tablets In The U.S. Market | www.medicalnewstoday.com
Author: GLG Member Program Contributor

Carvidolol is an excellent drug indicated for the treatment of CHF Very Expensive drug on restricted formulary by many HMOs A good news to many physicians who were restricted in using this drug.

Posted September 10, 2007

Novartis's Tekturna shows promise in heart failure
Analysis of: Novartis's Tekturna shows promise in heart failure | www.reuters.com
Author: GLG Member Program Contributor

RAAS inhibition at many levels is an exciting idea! New Class of antihypertensive is welcomed by many physicians who struggle with BP controll in many of their HTN patients.

Posted September 7, 2007

Merck 'good' cholesterol drug meets trial goals
Analysis of: Merck 'good' cholesterol drug meets trial goals | www.therapeuticsdaily.com
Author: GLG Member Program Contributor

Merck is clearly trying to tap into Abbot and Pfizers share of the cardiovascular market. The drug Cordaptive has packaging or formulation issues that spell regulatory delay.

Posted September 7, 2007

Novartis's Tekturna shows promise in heart failure
Analysis of: Novartis's Tekturna shows promise in heart failure | www.reuters.com
Author: GLG Member Program Contributor

1) The different mechanisms of action for Diovan which reduces blood pressure by targeting angiotensin receptors, and while Tekturna blocks renin, a kidney enzyme that triggers a process in hypertension make them somewhat non-competitive. Tekturna is a good addition to the cardiovascular regime that...

Posted September 7, 2007

Drug-Coated Stents Are Questioned
Analysis of: Drug-Coated Stents Are Questioned | online.wsj.com
Author: GLG Member Program Contributor

There is great controversy in the literature and among physicians of the risk/benfit ratio in using drug eluting stents over bare metal. This study, though observational, just raises more issues and doubts about the safety and benefit of drug eluting stents.

Posted September 7, 2007

Novartis's Tekturna shows promise in heart failure
Analysis of: Novartis's Tekturna shows promise in heart failure | www.reuters.com
Author: GLG Member Program Contributor

As we are all aware now tratment of CHF involves using medication that affects neurohormonal pathways. The renin-angiotensin system is one of thes pathways. A direct renin inhibitor would be expected to modify this pathway and so have an effect. Will it be better than the ACE inhibitors is the real...

Posted September 7, 2007

Merck 'good' cholesterol drug meets trial goals
Analysis of: Merck 'good' cholesterol drug meets trial goals | www.therapeuticsdaily.com
Author: GLG Member Program Contributor

New Merck drug Cordaptive raises HDL-C but may have adverse events. Dr. Steven Nissen of the Cleveland Clinic believes safety issues need to be addressed. When Dr. Nissen speaks, the world usually listens. His analysis has recently been the stimulus for the bad press of Avandia, BMS's diabetes...

Posted September 7, 2007

Merck 'good' cholesterol drug meets trial goals
Analysis of: Merck 'good' cholesterol drug meets trial goals | www.therapeuticsdaily.com
Author: GLG Member Program Contributor

Current therapy for increasing HDL ("good cholesterol") is limited by side effects - this drug increases HDL without the side effects - could be a blockbuster

Posted September 7, 2007

Novartis's Tekturna shows promise in heart failure
Analysis of: Novartis's Tekturna shows promise in heart failure | www.reuters.com
Author: GLG Member Program Contributor

- drug is designed to treat congestive heart failure - BNP (basal naturietic protein) is a serum marker for heart failure (CHF) - this new drug has been proven to lower BNP but NOT proven to improve CHF

Posted September 7, 2007
Hello, I'm here to sell you Allegra D, and Xyzal, but not Allegra or Zyrtec!
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: David Engler, Physician The Allergy Clinic

Take Zyrtec and sort out the right-handed molecules from the lefties. Send all the lefties home, and you have levocetirizine, a.k.a. Xyzal. Like Zyrtec, Xyzal is owned by UCB http://www.ucb-pharma.com/products/ . But unlike Zyrtec, Xyzal will not be marketed by Pfizer. Instead,...

Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 395

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-06T21:45:17.077

All GLG News Analyses Filed Under: Cardiology

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare